Journal: Journal of Medicinal Chemistry

Article Title: RTx-303, an Orally Bioavailable Polθ Polymerase Inhibitor That Potentiates PARP Inhibitors in BRCA Mutant Tumors

doi: 10.1021/acs.jmedchem.5c00551

Figure Lengend Snippet: Cellular and in vitro activity of RTx-284. A. Bar plot showing the IC50 of RTx-284 in the indicated HR-proficient (gray) and HRD (red) cell lines. Data represent mean of at least 3 independent experiments performed in triplicate. B-D. Synergy plots created by Combenefit showing synergistic activity between RTx-284 and indicated PARPi in the indicated HRD cell lines. E. Bar plot showing that 10 μM RTx-284 suppresses the MMEJ GFP reporter. Data represent mean of 3 individual experiments performed in triplicate ±SEM. F. Dot plot showing increase of γH2AX following RTx-284:olaparib treatment in DLD1 BRCA2–/– cells. G. Bar plot showing that RTx-284 promotes an increase in caspase positive DLD1 BRCA2–/– cells. Data represent mean of 3 independent experiments performed in triplicate, ±SEM.

Article Snippet: HCT 116 BRCA2 −/– and HCT 116 Parental were obtained from Cancertools, London, UK.

Techniques: In Vitro, Activity Assay

Journal: Journal of Medicinal Chemistry

Article Title: RTx-303, an Orally Bioavailable Polθ Polymerase Inhibitor That Potentiates PARP Inhibitors in BRCA Mutant Tumors

doi: 10.1021/acs.jmedchem.5c00551

Figure Lengend Snippet: RTx-303 potentiates PARPi in BRCA mutant cells and xenografts. A. Scatter plot showing relative viability of the indicated ID8 cells treated with the indicated concentrations of olaparib with and without 5 μM RTx-303. Data represent mean of 3 independent experiments performed in triplicate, ±SEM. B. Scatter plot showing BRCA2 mutant BR-05–0566 PDX volumes following treatment with vehicle, 45 mg/kg olaparib (PO,QD), 60 mg/kg RTx-303 (PO,BID), and 45 mg/kg olaparib (PO,QD) with 60 mg/kg RTx-303 (PO,BID) (left). Scatter plot showing % body weight change (right). Data represent mean, n = 7 ±SEM. C. Scatter plot showing BRCA2 mutant BR-05–0568 PDX volumes following treatment with vehicle, 0.12 mg/kg talazoparib (PO,QD) with and without 60 mg/kg RTx-303 (PO,BID) (left). Scatter plot showing % body weight change. (right). Data represent mean, n = 6 ±SEM. D. Scatter plot showing MDA-MB-436 tumor volumes following treatment with vehicle, 45 mg/kg olaparib (PO,QD) with and without 60 mg/kg RTx-303 (PO,BID) (left). Scatter plot showing % body weight change (right). Data represent mean, n = 8 ±SEM. * p < 0.05, *** p < 0.001.

Article Snippet: HCT 116 BRCA2 −/– and HCT 116 Parental were obtained from Cancertools, London, UK.

Techniques: Mutagenesis

Journal: Biomarker Insights

Article Title: mRNA Expression and Methylation of the RAD51 , ATM , ATR , BRCA1 , and BRCA2 Genes in Gastric Adenocarcinoma

doi: 10.1177/11772719231225206

Figure Lengend Snippet: RAD51 , ATR , BRCA1 , BRCA2 , and ATM mRNA expression in gastric adenocarcinoma and non-tumor gastric mucosa samples.

Article Snippet: The following antibodies were used: ATM (St John’s Laboratory, London, UK, STJ97797, 1:400), ATR (Abcam, Cambridge, UK, ab178407, 1:100), BRCA1 (St John’s Laboratory, STJ113833, 1:300), RAD51 (St John’s Laboratory, STJ95330, 1:100), and BRCA2 (St John’s Laboratory, STJ91885, 1:100).

Techniques: Expressing

Journal: Biomarker Insights

Article Title: mRNA Expression and Methylation of the RAD51 , ATM , ATR , BRCA1 , and BRCA2 Genes in Gastric Adenocarcinoma

doi: 10.1177/11772719231225206

Figure Lengend Snippet: Comparison of RAD51 , ATR , BRCA1 , BRCA2 , and ATM mRNA expression in tumor and non-tumor mucosa, considering the paired samples of the same individuals. The results are presented in box plots, using a logarithmic scale (+1 was added as a constant to allow the logarithmic representation of null values).

Article Snippet: The following antibodies were used: ATM (St John’s Laboratory, London, UK, STJ97797, 1:400), ATR (Abcam, Cambridge, UK, ab178407, 1:100), BRCA1 (St John’s Laboratory, STJ113833, 1:300), RAD51 (St John’s Laboratory, STJ95330, 1:100), and BRCA2 (St John’s Laboratory, STJ91885, 1:100).

Techniques: Comparison, Expressing

Journal: Biomarker Insights

Article Title: mRNA Expression and Methylation of the RAD51 , ATM , ATR , BRCA1 , and BRCA2 Genes in Gastric Adenocarcinoma

doi: 10.1177/11772719231225206

Figure Lengend Snippet: Comparison between RAD51 , ATR , BRCA1 , BRCA2 , and ATM mRNA expression in patients with previous neoadjuvant chemotherapy and in those without neoadjuvant chemotherapy, considering tumor samples and non-tumor mucosa samples.

Article Snippet: The following antibodies were used: ATM (St John’s Laboratory, London, UK, STJ97797, 1:400), ATR (Abcam, Cambridge, UK, ab178407, 1:100), BRCA1 (St John’s Laboratory, STJ113833, 1:300), RAD51 (St John’s Laboratory, STJ95330, 1:100), and BRCA2 (St John’s Laboratory, STJ91885, 1:100).

Techniques: Comparison, Expressing

Journal: Biomarker Insights

Article Title: mRNA Expression and Methylation of the RAD51 , ATM , ATR , BRCA1 , and BRCA2 Genes in Gastric Adenocarcinoma

doi: 10.1177/11772719231225206

Figure Lengend Snippet: Association between immunohistochemistry and mRNA levels in tumor samples.

Article Snippet: The following antibodies were used: ATM (St John’s Laboratory, London, UK, STJ97797, 1:400), ATR (Abcam, Cambridge, UK, ab178407, 1:100), BRCA1 (St John’s Laboratory, STJ113833, 1:300), RAD51 (St John’s Laboratory, STJ95330, 1:100), and BRCA2 (St John’s Laboratory, STJ91885, 1:100).

Techniques: Immunohistochemistry

Journal: Biomarker Insights

Article Title: mRNA Expression and Methylation of the RAD51 , ATM , ATR , BRCA1 , and BRCA2 Genes in Gastric Adenocarcinoma

doi: 10.1177/11772719231225206

Figure Lengend Snippet: Correlation between RAD51 , ATR , BRCA1 , BRCA2 , and ATM mRNA expression and histological type, histological grade, perineural invasion, and vascular invasion in tumor samples.

Article Snippet: The following antibodies were used: ATM (St John’s Laboratory, London, UK, STJ97797, 1:400), ATR (Abcam, Cambridge, UK, ab178407, 1:100), BRCA1 (St John’s Laboratory, STJ113833, 1:300), RAD51 (St John’s Laboratory, STJ95330, 1:100), and BRCA2 (St John’s Laboratory, STJ91885, 1:100).

Techniques: Expressing

Journal: Biomarker Insights

Article Title: mRNA Expression and Methylation of the RAD51 , ATM , ATR , BRCA1 , and BRCA2 Genes in Gastric Adenocarcinoma

doi: 10.1177/11772719231225206

Figure Lengend Snippet: Correlation between RAD51 , ATR , BRCA1 , BRCA2 , and ATM mRNA expression and depth of invasion (pT), regional lymph node metastasis, distant metastasis, and stage in tumor samples.

Article Snippet: The following antibodies were used: ATM (St John’s Laboratory, London, UK, STJ97797, 1:400), ATR (Abcam, Cambridge, UK, ab178407, 1:100), BRCA1 (St John’s Laboratory, STJ113833, 1:300), RAD51 (St John’s Laboratory, STJ95330, 1:100), and BRCA2 (St John’s Laboratory, STJ91885, 1:100).

Techniques: Expressing

Journal: Biomarker Insights

Article Title: mRNA Expression and Methylation of the RAD51 , ATM , ATR , BRCA1 , and BRCA2 Genes in Gastric Adenocarcinoma

doi: 10.1177/11772719231225206

Figure Lengend Snippet: Comparison between the mRNA levels in the tumors of patients who died and those who did not, considering the following groups: total population, excluding neoadjuvant therapy, with only surgical treatment, and with adjuvant or neoadjuvant treatment.

Article Snippet: The following antibodies were used: ATM (St John’s Laboratory, London, UK, STJ97797, 1:400), ATR (Abcam, Cambridge, UK, ab178407, 1:100), BRCA1 (St John’s Laboratory, STJ113833, 1:300), RAD51 (St John’s Laboratory, STJ95330, 1:100), and BRCA2 (St John’s Laboratory, STJ91885, 1:100).

Techniques: Comparison, Adjuvant

Journal: Biomarker Insights

Article Title: mRNA Expression and Methylation of the RAD51 , ATM , ATR , BRCA1 , and BRCA2 Genes in Gastric Adenocarcinoma

doi: 10.1177/11772719231225206

Figure Lengend Snippet: Kaplan-Meier curves comparing the overall survival of the 24 patients with tumor mRNA expression above the median with that of the 24 below the median, for RAD51 , ATR , BRCA1 , BRCA2 , and ATM .

Article Snippet: The following antibodies were used: ATM (St John’s Laboratory, London, UK, STJ97797, 1:400), ATR (Abcam, Cambridge, UK, ab178407, 1:100), BRCA1 (St John’s Laboratory, STJ113833, 1:300), RAD51 (St John’s Laboratory, STJ95330, 1:100), and BRCA2 (St John’s Laboratory, STJ91885, 1:100).

Techniques: Expressing

Journal: Oncology Letters

Article Title: Expression characteristics of FHIT , p53 , BRCA2 and MLH1 in families with a history of oesophageal cancer in a region with a high incidence of oesophageal cancer

doi: 10.3892/ol.2014.2682

Figure Lengend Snippet: Breast cancer type 2 susceptibility protein (BRCA2) immune response in oesophageal carcinoma tissues. (A) Strong and positive reaction for BRCA2 expression. Immunoreactivity was predominantly located in the cytoplasm and cell membrane; a positive cancer cell is shown by the arrow. (B) Weak and positive reaction for BRCA2 expression. Immunoreactivity was predominantly located in the cytoplasm and membrane; a positive cancer cell is shown by the arrow. (C) Negative expression for BRCA2; a negatively expressed cell is shown by the arrow. Magnification, ×400; haematoxylin and eosin restained.

Article Snippet: Subsequently, 0.5% H 2 O 2 was added to MLH1 at room temperature for 20 min and the resulting mixture was washed three times with PBS for 5 min. BRCA2 rabbit anti-human polyclonal antibody was purchased from Boster Biological Engineering Co., Ltd., (Wuhan, China; dilution 1:100), MLH1 rat anti-horse monoclonal antibody was purchased from BD Pharmingen (San Diego, CA, USA; dilution, 1:50), the FHIT polyclonal rabbit anti-goat antibody was purchased from Beijing Zhongshan Biotechnology Co., Ltd. (Beijing, China) (ZA-0410; 1:100 dilution) and p53 rat anti-horse monoclonal antibody (1:1,000) was purchased from Nuclea Biotechnologies, Inc., (Pittsfield, MA, USA).

Techniques: Expressing, Membrane

Journal: Oncology Letters

Article Title: Expression characteristics of FHIT , p53 , BRCA2 and MLH1 in families with a history of oesophageal cancer in a region with a high incidence of oesophageal cancer

doi: 10.3892/ol.2014.2682

Figure Lengend Snippet: Correlation analysis of BRCA2 , p53 , MLH1 and FHIT expression in the cancer tissues of oesophageal carcinoma patients with or without a family history of oesophageal cancer.

Article Snippet: Subsequently, 0.5% H 2 O 2 was added to MLH1 at room temperature for 20 min and the resulting mixture was washed three times with PBS for 5 min. BRCA2 rabbit anti-human polyclonal antibody was purchased from Boster Biological Engineering Co., Ltd., (Wuhan, China; dilution 1:100), MLH1 rat anti-horse monoclonal antibody was purchased from BD Pharmingen (San Diego, CA, USA; dilution, 1:50), the FHIT polyclonal rabbit anti-goat antibody was purchased from Beijing Zhongshan Biotechnology Co., Ltd. (Beijing, China) (ZA-0410; 1:100 dilution) and p53 rat anti-horse monoclonal antibody (1:1,000) was purchased from Nuclea Biotechnologies, Inc., (Pittsfield, MA, USA).

Techniques: Expressing

Journal: Oncology Letters

Article Title: Expression characteristics of FHIT , p53 , BRCA2 and MLH1 in families with a history of oesophageal cancer in a region with a high incidence of oesophageal cancer

doi: 10.3892/ol.2014.2682

Figure Lengend Snippet: Correlation analysis of BRCA2 , p53 and MLH1 expression in the cancer tissues of oesophageal carcinoma patients with or without a family history of oesophageal cancer.

Article Snippet: Subsequently, 0.5% H 2 O 2 was added to MLH1 at room temperature for 20 min and the resulting mixture was washed three times with PBS for 5 min. BRCA2 rabbit anti-human polyclonal antibody was purchased from Boster Biological Engineering Co., Ltd., (Wuhan, China; dilution 1:100), MLH1 rat anti-horse monoclonal antibody was purchased from BD Pharmingen (San Diego, CA, USA; dilution, 1:50), the FHIT polyclonal rabbit anti-goat antibody was purchased from Beijing Zhongshan Biotechnology Co., Ltd. (Beijing, China) (ZA-0410; 1:100 dilution) and p53 rat anti-horse monoclonal antibody (1:1,000) was purchased from Nuclea Biotechnologies, Inc., (Pittsfield, MA, USA).

Techniques: Expressing

Journal: Oncology Letters

Article Title: Expression characteristics of FHIT , p53 , BRCA2 and MLH1 in families with a history of oesophageal cancer in a region with a high incidence of oesophageal cancer

doi: 10.3892/ol.2014.2682

Figure Lengend Snippet: Association between BRCA2, MLH1 , FHIT and p53 positive expression and clinicopathological characteristics of oesophageal carcinoma.

Article Snippet: Subsequently, 0.5% H 2 O 2 was added to MLH1 at room temperature for 20 min and the resulting mixture was washed three times with PBS for 5 min. BRCA2 rabbit anti-human polyclonal antibody was purchased from Boster Biological Engineering Co., Ltd., (Wuhan, China; dilution 1:100), MLH1 rat anti-horse monoclonal antibody was purchased from BD Pharmingen (San Diego, CA, USA; dilution, 1:50), the FHIT polyclonal rabbit anti-goat antibody was purchased from Beijing Zhongshan Biotechnology Co., Ltd. (Beijing, China) (ZA-0410; 1:100 dilution) and p53 rat anti-horse monoclonal antibody (1:1,000) was purchased from Nuclea Biotechnologies, Inc., (Pittsfield, MA, USA).

Techniques: Expressing

Journal: Oncology Letters

Article Title: Expression characteristics of FHIT , p53 , BRCA2 and MLH1 in families with a history of oesophageal cancer in a region with a high incidence of oesophageal cancer

doi: 10.3892/ol.2014.2682

Figure Lengend Snippet: BRCA2 and MLH1 expression analysis in patients with a positive or negative family history of oesophageal carcinoma.

Article Snippet: Subsequently, 0.5% H 2 O 2 was added to MLH1 at room temperature for 20 min and the resulting mixture was washed three times with PBS for 5 min. BRCA2 rabbit anti-human polyclonal antibody was purchased from Boster Biological Engineering Co., Ltd., (Wuhan, China; dilution 1:100), MLH1 rat anti-horse monoclonal antibody was purchased from BD Pharmingen (San Diego, CA, USA; dilution, 1:50), the FHIT polyclonal rabbit anti-goat antibody was purchased from Beijing Zhongshan Biotechnology Co., Ltd. (Beijing, China) (ZA-0410; 1:100 dilution) and p53 rat anti-horse monoclonal antibody (1:1,000) was purchased from Nuclea Biotechnologies, Inc., (Pittsfield, MA, USA).

Techniques: Expressing

Journal:

Article Title: WDRPUH, A Novel WD-Repeat-Containing Protein, Is Highly Expressed in Human Hepatocellular Carcinoma and Involved in Cell Proliferation 1 *

doi:

Figure Lengend Snippet: Interaction of WDRPUH with HSP70, CCT1-δ, CCT1-α, or BRCA2. HEK293 cells were transiently transfected with p3xFLAG-WDRPUH or p3xFLAG empty vector (Mock). Cell lysates were immunoprecipitated with anti-FLAG M2 antibody (mouse) conjugated with agarose beads or specific antibodies to interacting protein. (A and B) Coimmunoprecipitation of FLAG-WDRPUH and endogenous HSP70. Whole cell extracts from the cells exogenously expressing FLAG-WDRPUH were used as positive controls. (C) Coimmunoprecipitation of FLAG-WDRPUH and endogenous CCT1-δ. (D) Coimmunoprecipitation of FLAG-WDRPUH and endogenous CCT1-α. (E and F) Coimmunoprecipitation of FLAG-WDRPUH and endogenous BRCA2.

Article Snippet: Proteins were separated by 10% SDS-PAGE and immunoblotted with mouse anti-FLAG M2 (Sigma) antibody, anti-HSP70 antibody (Stressgen, Victoria, Canada), anti-chaperonin-containing TCP-1 (CCT1) delta subunity (Santa Cruz Biotechnology, Santa Cruz, CA), anti-CTT1-alpha subunity (Stressgen), or anti-BRCA2 (Stressgen).

Techniques: Transfection, Plasmid Preparation, Immunoprecipitation, Expressing